Post-earnings recap
Reported
Thu, Jun 4, 2026
EPS actual
$1.21
EPS est.
$1.10
EPS surprise
+9.70%
1-day move
+2.78%
The Cooper Companies reported better-than-expected earnings per share, which likely contributed to the positive stock reaction, with shares rising 2.78%. However, there was no revenue figure provided, leaving some uncertainty about overall performance. Investors may be encouraged by the EPS beat, but the lack of additional context from management could lead to cautious sentiment moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.21 | $1.10 | +9.70% |
| Revenue | N/A | $1.1B | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
The Cooper Companies, Inc. is a healthcare company that specializes in the production of contact lenses and other eye care products. With a market cap of $15 billion, it plays a significant role in the health care supplies sector, which is increasingly focused on innovation and improving patient outcomes.
Last quarter
In Q1-2026, Cooper Companies reported an EPS of $1.18, exceeding expectations by nearly 15%. However, the stock experienced a slight decline of 2.17% the following day.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+38.59%
Avg 1-day reaction
-0.73%
Analysts are expecting solid performance from Cooper Companies, with a consensus EPS of $1.10 and revenue of $1.1 billion. The company has consistently beaten EPS estimates in recent quarters.
Bull case
If Cooper Companies continues its trend of beating EPS estimates, it could signal strong operational efficiency and market demand, potentially driving the stock higher.
Bear case
On the other hand, any signs of slowing revenue growth or increased costs could raise concerns about the company's future profitability, leading to a negative market reaction.
Key metrics to watch
EPS
$1.10Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$1.1BTotal revenue reflects the company's ability to generate sales and is crucial for assessing growth.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $1.10?
A beat on EPS could reinforce investor confidence and suggest strong demand for the company's products.
Q2
What are the revenue growth projections for the upcoming quarters?
Guidance on revenue growth will be critical for assessing the company's future performance and market position.
—
Est. EPS
$2.28
Est. Rev
$1.8B
Impl. Move
±8.2%
Why consensus could be wrong
The consensus may underestimate the company's ability to capitalize on emerging markets and new product launches, which could drive higher-than-expected growth.
Supporting evidence
The company has consistently beaten EPS estimates in the past, indicating strong operational management.
Options pricing suggests a higher volatility expectation than historical averages, hinting at potential surprises.
Recent trends in the healthcare sector indicate a growing demand for eye care products, which Cooper Companies is well-positioned to meet.
Key risk
If revenue growth exceeds expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on whether Cooper Companies can maintain its momentum in a competitive market.
Bull confirmed if
An EPS of $1.15 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $1.05 would support the bear case, suggesting potential challenges in growth or profitability.
What the market is pricing for the move.
Implied Move
±10.43%
Historical Avg
±1.9%
The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.
Options are pricing ±10.4% while COO has averaged ±1.9% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
23.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cooper Companies beats expectations, history suggests the stock could rise by an average of 0.95%, confirming strong operational performance.
In line / cautious
If results are in line with expectations, the stock may experience muted movement, reflecting cautious investor sentiment.
Miss
A miss on EPS could lead to a decline in stock price, with historical patterns indicating a potential drop of around 0.40%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
2 buys·0 sells
Members
1
House only
Est. Notional
$2,002.00–$30,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
Net buying
Recent Transactions
Traded Jun 5, 2026 · disclosed Jul 2, 2026
$1,001.00–$15,000.00
Traded May 29, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.